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Fostering collaboration 
on post-Ebola clinical 
research in Liberia
Despite evidence pointing to the pre-
2014 existence of Ebola virus disease 
(EVD) in west Africa,1 the current 
outbreak is the largest and longest 
yet.2,3 The urgent need to contain the 
epidemic focused the global research 
response on vaccines, therapeutics, 
and diagnostic tools. Yet the epidemic 
overstretched and outpaced the capacity 
of affected countries’ health systems 
to respond to the health needs of its 
citizens; the global call for researchers 
to conduct clinical trials similarly 
overwhelmed ethical and regulatory 
capacities. Here we describe a successful 
research partnership set up during the 
outbreak between Liberia and the USA.
In August, 2014, Walter T Gwenigale, 
then the Minister of Health of Liberia, 
wrote to the US Department of Health 
& Human Services (DHHS) requesting 
assistance to foster collaboration over 
research on promising vaccines and 
thera peutics for EVD. DHHS Secretary 
Sylvia Burwell affirmed the need to 
initiate an Ebola research partnership. 
US National Institutes of Health (NIH) 
Deputy Director for Clinical Research 
and Special Projects Clifford Lane 
then presented a concept to Liberia’s 
Ministry of Health for the establish-
ment of a Joint Liberia–US Clinical 
Research Partner ship Program. Two 
key research agencies were identiﬁ ed 
by the respective governments to 
spearhead this proposed initiative: 
the Liberia Institute for Biomedical 
Research (LIBR) and the US NIH.
This initial concept led to the 
establishment of the Partnership for 
Research on Ebola Virus Disease in 
Liberia (PREVAIL), with an initial focus 
on EVD vaccines and therapeutics, 
and a long-term goal of establishing 
a clinical research centre of excellence. 
From October to December, 2014, 
Liberian and US researchers estab lished 
the appropriate partner ship platforms, 
including an operational plan and 
support-system-based organogram, 
to commence a clinical trial during the 
Ebola outbreak in Liberia. To jump-
start the proposed clinical research 
programme and simultaneously 
address the need to combat the 
prevailing EVD epidemic, three clinical 
studies were designed and approved by 
Liberian and US researchers, and rapidly 
implemented as the beginning of a 
sustainable long-term collaborative 
partnership between the two countries: 
PREVAIL I, an Ebola vaccine clinical 
trial; PREVAIL II, a multicountry Ebola 
treatment clinical trial; and PREVAIL III, 
an Ebola natural history study of EVD 
survivors and their close contacts.
Experience from Liberia shows 
that high-quality clinical trials, based 
on rigorous research methods, can 
be effectively imple mented during 
outbreaks.4 However, they must be 
grounded within the framework of 
a col laborative research partnership 
that strengthens ethical and regu-
latory systems, harnesses cultural 
com petencies via communication 
and social mobilisation, and supports 
infrastructure and capacity enhance-
ments.
Moving forward, there is an urgent 
need to evaluate and address Liberia’s 
capacity to appropriately beneﬁ t from 
the upsurge in research opportunities 
during the post-EVD period. Funding 
should be dedicated to developing a 
critical mass of skilled researchers who 
can lead clinical research programmes 
that are locally relevant, ethical, and 
methodologically sound.
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